FISH Probe Market Growth, Opportunities and Forecast To 2026 | Oxford Gene Technology; Mirus Bio LLC; Agilent Technologies; Perkin Elmer Inc.

[sara James]

The global Fluorescent In Situ Hybridization (Fish) Probe Market size is expected to reach USD 1.04 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 6.8% during the forecast period. Increasing global population prone to target diseases and demand for accurate and effective diagnostics of these diseases are the factors attributed to the growth. Increasing use of FISH probes in vitro diagnosis of various infectious diseases is expected to create growth opportunities in near future.

In addition, supportive government initiatives, rising healthcare expenditure and awareness pertaining to the benefits associated with FISH probe technique are expected to drive the market growth during forecast period. Furthermore, technological advancement in Chromogenic In Situ Hybridization (CISH) such as higher storage time for analyzed samples for long duration studies is expected to fuel the demand.

FISH is most commonly used for the detection of genetic diseases such as Angelman syndrome, Prader-Willi syndrome, chronic myelogenous leukemia, Down’s syndrome, Velocardiofacial syndrome, 22q13 deletion syndrome, acute lymphoblastic leukemia, and cri-du-chat. The genetic disease segment led the overall market in 2018. The probe does not require live cells and can quantify automatically as compared to the conventional cytogenetics, and is more convenient and effective. This factor is anticipated to propel the segment growth. According to a publication from the Centers for Disease Control and Prevention (CDC) in 2018, Down’s syndrome was the most common genetic disorders with almost one in every 700 new newborns affected by the disorder.

Related Press Release@ FISH Probe Market

FISH Probe Market Report Highlights

• Companion diagnostics is expected to command the largest market share of end use segment. Used in personalized medicine, it includes medical decision, products, and practices based on patient’s genetic, clinical, and genomic information
• In oncology, major companion diagnostics are based on the FISH owing to higher reliability, sensitivity, accuracy, and procedure reproducibility, which are less affected by analytical variables and tissue fixation as compared to immunohistochemistry
• miRNA is expected to be the fastest growing RNA segment, driven by factors such as increasing R&D and extensive usage in cancer detection
• Asia Pacific is expected to showcase lucrative growth over the forecast period due to rising per capita healthcare expenditure, improving healthcare facilities, and demand for IVD testing for disease detection
• Increasing R&D activities pertaining to cancer diagnostics and investment by private and government sector into biotech industry in Asia Pacific are the factors responsible for the growth
• Key players operating in the Fluorescent In Situ Hybridization (FISH) probe market include Oxford Gene Technology; Mirus Bio LLC; Agilent Technologies; Perkin Elmer Inc.; Genemed Biotechnologies Inc.; Horizon Diagnostics; BioDot Inc.; Sigma Aldrich; Life Science Technologies; GSP Research Institute Co., Ltd; Abnova Corporation; Biosearch Technologies; F Hoffman La Roche AG; Bio Care Medical LLC; EXIQON; and Affymetrix Panomics